Efficacy of treatment with ranibizumab in patients with wet age-related macular degeneration in routine clinical care: Data from the COMPASS health services research

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 252, Issue 4, 2014, Pages 647-655

  Wolf, Armin ^a   Kampik, Anselm ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Age related macular degeneration; Intravitreal injections; Neovascular age related macular degeneration; Non interventional study; Ranibizumab; Visual acuity

Indexed keywords

RANIBIZUMAB;

AGED; ARTICLE; BENIGN TUMOR; CLINICAL ASSESSMENT; CLINICAL EVALUATION; DRUG EFFICACY; DRUG TOLERABILITY; EYE DISEASE; EYE EXAMINATION; FEMALE; FOLLOW UP; GERMANY; HEALTH CARE SYSTEM; HEALTH SERVICES RESEARCH; HEART DISEASE; HUMAN; INJECTION; INJURY; INTOXICATION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MEDICAL CARE; MULTICENTER STUDY; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETINA MACULA AGE RELATED DEGENERATION; RETREATMENT; SELF EVALUATION; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HEALTH SERVICES RESEARCH; HUMANS; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RETREATMENT; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84897576281     PISSN: 0721832X     EISSN: 1435702X     Source Type: Journal    
DOI: 10.1007/s00417-013-2562-6     Document Type: Article

References (26)

1. Jager RD, Mieler WF, Miller JW (2008) Age-related macular degeneration. N Engl J Med 358:2606-2617
2. Kirchhof B (2000) Die altersabhangige Makuladegeneration. Dt Arztebl 97:1458-1462
3. Pauleikhoff D, Scheider A, Wiedmann P, Gelisken F, Scholl HP, Roider I, Mohr A, Zlateva G, Xu X (2009) Neovascular age-related macular degeneration in Germany. Encroachment on the quality of life and the financial implications. Ophthalmologe 106:242-251
4. Finger RP, Fimmers R, Holz FG, Scholl HP (2011) Incidence of blindness and severe visual impairment in Germany: projections for 2030. Investig Ophthalmol Vis Sci 52:4381-4389
5. Augood CA, Vingerling JR, de Jong PT, Chakravarthy U, Seland J, Soubrane G, Tomazzoli L, Topouzis F, Bentham G, Rahu M, Vioque J, Young IS, Fletcher AE (2006) Prevalence of age-related maculopathy in older Europeans: the European Eye Study (EUREYE). Arch Ophthalmol 124:529-535
6. Ferris FL 3rd, Fine SL, Hyman L (1984) Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol 102:1640-1642
7. Kliffen M, Sharma HS, Mooy CM, Kerkvliet S, de Jong PT (1997) Increased expression of angiogenic growth factors in age-related maculopathy. Br J Ophthalmol 81:154-162
8. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419-1431
9. Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T (2009) Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 116:e55
10. Current opinion of the German Ophthalmological Society, and the Retina Society the Professional Association of German Ophthalmologists. The anti-VEGF therapy for neovascular age-related macular degeneration: Therapeutic Strategies., 2012. Availiable at http://www.dog.org/wp-content/uploads/2009/08/ Stellungnahme-Anti-VEGF-Therapie-bei-der-neovaskul%C3%A4ren-Therapeutische- Strategie-Febr-2012-final1.pdf. Accessed 25 June 2012
11. Abraham P, Yue H, Wilson L (2010) Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2. Am J Ophthalmol 150:e311
12. Regillo CD, Brown DM, Abraham P, Yue H, Ianchulev T, Schneider S, Shams N (2008) Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 145:239-248
13. Fung AE, Lalwani GA, Rosenfeld PJ, Dubovy SR, Michels S, Feuer WJ, Puliafito CA, Davis JL, Flynn HW Jr, Esquiabro M (2007) An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 143:566-583
14. Jeganathan VS, Verma N (2009) Safety and efficacy of intravitreal anti-VEGF injections for age-related macular degeneration. Curr Opin Ophthalmol 20:223-225
15. Novartis Pharma GmbH. Fachinformation Lucentis: Rote Liste GmbH, September 2011. Accessed 25 June 2012
16. Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ (2011) Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 364:1897-1908
17. Holz FG, Amoaku W, Donate J, Guymer RH, Kellner U, Schlingemann RO, Weichselberger A, Staurenghi G (2011) Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study. Ophthalmology 118:663-671
18. Lalwani GA, Rosenfeld PJ, Fung AE, Dubovy SR, Michels S, Feuer W, Davis JL, Flynn HW Jr, Esquiabro M (2009) A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol 148:e41
19. Cohen SY, Dubois L, Tadayoni R, Fajnkuchen F, Nghiem-Buffet S, Delahaye-Mazza C, Guiberteau B, Quentel G (2009) Results of one-year's treatment with ranibizumab for exudative age-related macular degeneration in a clinical setting. Am J Ophthalmol 148:409-413
20. Dadgostar H, Ventura AA, Chung JY, Sharma S, Kaiser PK (2009) Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration. Ophthalmology 116:1740-1747
21. Holz FG, Korobelnik JF, Lanzetta P, Mitchell P, Schmidt-Erfurth U, Wolf S, Markabi S, Schmidli H, Weichselberger A (2010) The effects of a flexible visual acuity-driven ranibizumab treatment regimen in age-related macular degeneration: outcomes of a drug and disease model. Investig Ophthalmol Vis Sci 51:405-412
22. Wolf A, Reznicek L, Muhr J, Ulbig M, Kampik A, Haritoglou C (2012) Treatment of recurrent neovascular age-related macular degeneration with ranibizumab according to the PrONTO scheme. Ophthalmologe. doi: 10.1007/s00347-012-2717-6
23. Kaiser PK, Blodi BA, Shapiro H, Acharya NR (2007) Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 114:1868-1875
24. Muether PS, Hermann MM, Viebahn U, Kirchhof B, Fauser S (2012) Vascular endothelial growth factor in patients with exudative age-related macular degeneration treated with ranibizumab. Ophthalmology 119:2082-2086
25. Heimes B, Lommatzsch A, Zeimer M, Gutfleisch M, Spital G, Dietzel M, Pauleikhoff D (2011) Long-term visual course after anti-VEGF therapy for exudative AMD in clinical practice evaluation of the German reinjection scheme. Graefes Arch Clin Exp Ophthalmol 249:639-644
26. European Medicines Agency. Summary of Product characteristics. 23 August 2012. Availiable at http://www.ema.europa.eu/docs/en-GB/document-library/EPAR- Product-Information/human/000715/WC500043546.pd. Accessed 26/09/12